301 related articles for article (PubMed ID: 35087526)
1. Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of 'Almost Natural' Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection.
Klewinghaus D; Pekar L; Arras P; Krah S; Valldorf B; Kolmar H; Zielonka S
Front Immunol; 2021; 12():801368. PubMed ID: 35087526
[TBL] [Abstract][Full Text] [Related]
2. Milking the Cow: Cattle-Derived Chimeric Ultralong CDR-H3 Antibodies and Their Engineered CDR-H3-Only Knobbody Counterparts Targeting Epidermal Growth Factor Receptor Elicit Potent NK Cell-Mediated Cytotoxicity.
Pekar L; Klewinghaus D; Arras P; Carrara SC; Harwardt J; Krah S; Yanakieva D; Toleikis L; Smider VV; Kolmar H; Zielonka S
Front Immunol; 2021; 12():742418. PubMed ID: 34759924
[TBL] [Abstract][Full Text] [Related]
3. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
[TBL] [Abstract][Full Text] [Related]
4. Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture.
Bogen JP; Carrara SC; Fiebig D; Grzeschik J; Hock B; Kolmar H
Front Immunol; 2021; 12():669496. PubMed ID: 34040611
[TBL] [Abstract][Full Text] [Related]
5. CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies.
Fernández-Quintero ML; Kroell KB; Grunewald LJ; Fischer AM; Riccabona JR; Liedl KR
MAbs; 2022; 14(1):2024118. PubMed ID: 35090383
[TBL] [Abstract][Full Text] [Related]
6. Constant domain-exchanged Fab enables specific light chain pairing in heterodimeric bispecific SEED-antibodies.
Dietrich S; Gross AW; Becker S; Hock B; Stadlmayr G; Rüker F; Wozniak-Knopp G
Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140250. PubMed ID: 31295556
[TBL] [Abstract][Full Text] [Related]
7. Elucidating heavy/light chain pairing preferences to facilitate the assembly of bispecific IgG in single cells.
Joshi KK; Phung W; Han G; Yin Y; Kim I; Sandoval W; Carter PJ
MAbs; 2019 Oct; 11(7):1254-1265. PubMed ID: 31286843
[TBL] [Abstract][Full Text] [Related]
8. Cattle-derived knob paratopes grafted onto peripheral loops of the IgG1 Fc region enable the generation of a novel symmetric bispecific antibody format.
Yanakieva D; Vollmer L; Evers A; Siegmund V; Arras P; Pekar L; Doerner A; Valldorf B; Kolmar H; Zielonka S; Krah S
Front Immunol; 2023; 14():1238313. PubMed ID: 37942319
[TBL] [Abstract][Full Text] [Related]
9. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
[TBL] [Abstract][Full Text] [Related]
10. Common light chain chickens produce human antibodies of high affinity and broad epitope coverage for the engineering of bispecifics.
Ching KH; Berg K; Reynolds K; Pedersen D; Macias A; Abdiche YN; Harriman WD; Leighton PA
MAbs; 2021; 13(1):1862451. PubMed ID: 33491549
[TBL] [Abstract][Full Text] [Related]
11. EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies.
Cooke HA; Arndt J; Quan C; Shapiro RI; Wen D; Foley S; Vecchi MM; Preyer M
MAbs; 2018; 10(8):1248-1259. PubMed ID: 30215570
[TBL] [Abstract][Full Text] [Related]
12. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
13. Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers.
Boje AS; Pekar L; Koep K; Lipinski B; Rabinovich B; Evers A; Gehlert CL; Krohn S; Xiao Y; Krah S; Zaynagetdinov R; Toleikis L; Poetzsch S; Peipp M; Zielonka S; Klausz K
MAbs; 2024; 16(1):2315640. PubMed ID: 38372053
[TBL] [Abstract][Full Text] [Related]
14. Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.
Choi BD; Gedeon PC; Kuan CT; Sanchez-Perez L; Archer GE; Bigner DD; Sampson JH
J Immunol Methods; 2013 Sep; 395(1-2):14-20. PubMed ID: 23806556
[TBL] [Abstract][Full Text] [Related]
15. CDR-H3 diversity is not required for antigen recognition by synthetic antibodies.
Persson H; Ye W; Wernimont A; Adams JJ; Koide A; Koide S; Lam R; Sidhu SS
J Mol Biol; 2013 Feb; 425(4):803-11. PubMed ID: 23219464
[TBL] [Abstract][Full Text] [Related]
16. Influence of the bispecific antibody IgG subclass on T cell redirection.
Kapelski S; Cleiren E; Attar RM; Philippar U; Häsler J; Chiu ML
MAbs; 2019; 11(6):1012-1024. PubMed ID: 31242061
[TBL] [Abstract][Full Text] [Related]
17. A novel efficient bispecific antibody format, combining a conventional antigen-binding fragment with a single domain antibody, avoids potential heavy-light chain mis-pairing.
Huang S; Segués A; Hulsik DL; Zaiss DM; Sijts AJAM; van Duijnhoven SMJ; van Elsas A
J Immunol Methods; 2020 Aug; 483():112811. PubMed ID: 32569598
[TBL] [Abstract][Full Text] [Related]
18. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
19. The eIg technology to generate Ig-like bispecific antibodies.
Kühl L; Aschmoneit N; Kontermann RE; Seifert O
MAbs; 2022; 14(1):2063043. PubMed ID: 35427197
[TBL] [Abstract][Full Text] [Related]
20. The Unusual Genetics and Biochemistry of Bovine Immunoglobulins.
Stanfield RL; Haakenson J; Deiss TC; Criscitiello MF; Wilson IA; Smider VV
Adv Immunol; 2018; 137():135-164. PubMed ID: 29455846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
